Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BIO-205
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : MPM Capital
Deal Size : $30.0 million
Deal Type : Series A Financing
MPM backs new biotech in the hunt for non-opioid painkiller
Details : The financing will be used to advance the company’s lead program, BIO-205, through human proof-of-concept studies in neuropathic pain as well as to advance its portfolio of A3AR agonists.
Product Name : BIO-205
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 01, 2020
Lead Product(s) : BIO-205
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : MPM Capital
Deal Size : $30.0 million
Deal Type : Series A Financing